Stenocare ASFRA:S7C 34 EV-to-FCF is -11.42 as of Jul. 11, 2026. GuruFocus rates FRA:S7C with a GF Score™ of 34/100 and a GF Value™ of €0.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, Stenocare AS ranks worse than 177935.77% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Stenocare AS's Enterprise Value is €5.88 Mil.
Stenocare AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.52 Mil. Therefore, Stenocare AS's EV-to-FCF for today is -11.42.
The historical rank and industry rank for Stenocare AS's EV-to-FCF or its related term are showing as below:
FRA:S7C'
s EV-to-FCF Range Over the Past 10 Years
Min: -24.95 Med: -6.29 Max: -1.37
Current: -11.67
During the past 8 years, the highest EV-to-FCF of Stenocare AS was -1.37. The lowest was -24.95. And the median was -6.29.
FRA:S7C's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.765
vs FRA:S7C: -11.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stenocare AS's PE Ratio (TTM) for today is calculated as:
Stenocare AS's share price for today is €0.125.
Stenocare AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Stenocare AS EV-to-FCF Related Terms
Stenocare AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Stenocare AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Stenocare AS's EV-to-FCF falls into.
Stenocare AS's current Enterprise Value is €5.88 Mil.
Stenocare AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (FRA:S7C) has a EV-to-FCF of -11.42 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Stenocare AS's EV-to-FCF too high?
Stenocare AS's current EV-to-FCF is -11.42. Based on the distribution chart, Stenocare AS ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #999999 out of 562 companies for EV-to-FCF. This places Stenocare AS in the lower half of its industry. The industry median EV-to-FCF is 20.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.77, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Stenocare AS and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current EV-to-FCF is -11.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (FRA:S7C) is currently considered Possible Value Trap. The stock's GF Value™ is €0.29, compared to a current price of €0.13 — trading 56.9% below its estimated fair value. The current EV-to-FCF is -11.42. Stenocare AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current EV-to-FCF is -11.42 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.13 is trading 56.9% below its estimated GF Value™ of €0.29.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for FRA:S7C:
EV-to-FCF: -11.42
GF Value™: €0.29 vs. price of €0.13 (56.9% below fair value)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
34GF Score
Get the complete analysis for FRA:S7C
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
